• Jaguar Health highlighted additional data already presented at ESPGHAN 2026 on liquid oral crofelemer as an add-on therapy in pediatric intestinal failure.
• Ongoing studies indicated patients reduced reliance on parenteral support over more than a year of dosing, with tolerability described as favorable.
• The update supports continued development of crofelemer for rare conditions including microvillus inclusion disease and short bowel syndrome.
• Jaguar outlined a plan to seek Breakthrough Therapy designation for microvillus inclusion disease, with an NDA filing targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606300900ACCESSWRNAPR_____1184345) on June 30, 2026, and is solely responsible for the information contained therein.